Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ALD403
BIOLOGICAL
4 trials
Sponsors
Alder Biopharmaceuticals, Inc.
Conditions
Migraine
Migraine Disorders
Phase 1
Safety Tolerability and Pharmacokinetics of ALD403
Completed
NCT01579383
Alder Biopharmaceuticals, Inc.
Migraine Disorders
Start: 2012-04-30
End: 2013-04-30
Updated: 2013-04-26
Safety, Efficacy and Pharmacokinetics of ALD403
Completed
NCT01772524
Alder Biopharmaceuticals, Inc.
Migraine
Start: 2013-01-31
End: 2014-02-28
Updated: 2016-01-08
Phase 2
A Multicenter Assessment of ALD403 in Chronic Migraine
Completed
NCT02275117
Alder Biopharmaceuticals, Inc.
Migraine Disorders
Start: 2014-10-31
End: 2016-11-30
Updated: 2020-04-08
Phase 3
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Completed
NCT02559895
Alder Biopharmaceuticals, Inc.
Migraine Disorders
Start: 2015-09-30
End: 2017-12-31
Updated: 2020-05-14
Related Papers
Prevalence of Migraine in Saudi Arabia and the Proposed Introduction of Eptinezumab: A Pooled and Meta-Analysis from Clinical Rrials.
2024-04-30
Lack of “wearing off” effect with eptinezumab in the preventive treatment of migraine (P13-12.009)
Neurology
2023-04-25
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
BMC Neurology
2022-10-25
5 citations
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.
2022-04-18
6 citations
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
Cephalalgia
2022-03-18
22 citations
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
The Journal of Headache and Pain
2022-02-07
7 citations
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
Clinical Therapeutics
2022-02-05
17 citations
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
Cephalalgia Reports
2022-01-01
7 citations
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
2021-11-25
9 citations
P.034 Eptinezumab Demonstrated Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2021-11-01
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
The Journal of Headache and Pain
2021-03-29
45 citations
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Clinical Therapeutics
2020-11-27
53 citations
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Cephalalgia
2020-02-19
374 citations
Antibodies to watch in 2020.
2020-01-01
328 citations
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
Cephalalgia
2019-06-24
153 citations
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
2014-10-05
272 citations